Loading organizations...
§ Private Profile · Burlingame, CA, USA
Therapeutics developer creating targeted immunomodulatory therapies for ocular inflammation, focused on dry eye, uveitis, diabetic retinopathy, and.
Iolyx has raised $15.0M across 1 funding round.
Key people at Iolyx.
Iolyx has raised $15.0M in total across 1 funding round.
Iolyx Therapeutics, based in Menlo Park, California, develops targeted immunomodulatory therapies designed to address ocular inflammation affecting both the front and back of the eye. The company's scientific approach centers on restoring immune homeostasis, aiming to offer superior efficacy, safety, and convenience compared to traditional steroids and immunosuppressants currently utilized in ophthalmology. Their product pipeline specifically targets a range of vision-threatening inflammatory ocular diseases, encompassing chronic conditions like dry eye and ocular allergies. Furthermore, Iolyx focuses on more severe indications such as anterior and posterior uveitis, diabetic retinopathy, and age-related macular degeneration, which can lead to significant vision loss. The organization operates with fewer than 25 employees and generates less than $5 million in annual revenue. Its business model centers on sectors/customers: Immuno-ophthalmology, patients with vision-threatening inflammatory ocular diseases such as dry eye, ocular allergies, rosacea, anterior uveitis, posterior uveitis, diabetic retinopathy, and age-related macular degeneration.
Key people at Iolyx.
Iolyx has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Iolyx Therapeutics - Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2025 | $15M Series B | Daniel Estes | Gc&h Investments | Announced |
Iolyx has raised $15.0M in total across 1 funding round.
Iolyx's investors include Daniel Estes, GC&H Investments.
Iolyx Therapeutics is a biopharmaceutical company focused on transforming the treatment of ocular inflammatory diseases by developing targeted immuno-ophthalmology therapies. Their products are designed to precisely deliver immunomodulatory agents to relevant eye tissues, addressing inflammation at its source in both the "front of the eye" (ocular surface diseases like dry eye and ocular allergies) and the "back of the eye" (retinal and autoimmune-associated ocular diseases). Iolyx aims to provide safer, more effective, and more convenient alternatives to traditional steroids and immunosuppressants, which often have significant side effects and limited efficacy[1][2].
Their lead product candidate, ILYX-002, is in Phase II clinical trials for autoimmune-associated dry eye disease (keratoconjunctivitis sicca), with promising data supporting progression to late-stage development. The company recently secured a strategic partnership with Laboratoires Théa valued up to $280 million, which will accelerate commercialization and further pipeline development, reflecting strong growth momentum and investor confidence[2][3][4].
Iolyx Therapeutics was founded with the mission to address unmet needs in ocular inflammatory diseases by leveraging advances at the intersection of immunology and ophthalmology. While specific founding year and founders' details are not publicly highlighted, the company is headquartered in Menlo Park, California, and has evolved to focus on innovative, locally administered formulations that maximize therapeutic efficacy and safety. Early traction includes successful Phase II clinical data for ILYX-002 and the strategic licensing deal with Laboratoires Théa, marking pivotal moments that validate their scientific approach and commercial potential[1][2].
Iolyx is positioned at the convergence of immunology and ophthalmology, riding the trend toward precision medicine and targeted biologics in autoimmune and inflammatory diseases. The timing is favorable due to increasing recognition of ocular inflammation’s impact on quality of life and the limitations of existing treatments. Market forces such as an aging population, rising autoimmune disease prevalence, and demand for safer therapies support growth. By advancing novel immunomodulatory treatments, Iolyx influences the broader ecosystem by potentially setting new standards for ocular disease management and inspiring further innovation in localized drug delivery[1][2].
Looking ahead, Iolyx is poised to advance ILYX-002 into Phase III trials and expand its pipeline into additional autoimmune-associated retinal diseases. The partnership with Laboratoires Théa will be instrumental in scaling clinical development and eventual commercialization. Trends such as personalized medicine, improved drug delivery technologies, and growing investment in ophthalmic immunotherapies will shape their trajectory. Iolyx’s influence is likely to grow as they address significant unmet needs with targeted, safer therapies, potentially displacing steroids and older immunosuppressants in ocular care[2][3][4].
Their mission to transform immuno-ophthalmology aligns with broader healthcare shifts toward precision and patient-centric treatments, making Iolyx a notable innovator in the eye disease therapeutic landscape.
